首頁 › 多發性骨髓瘤 › 加州 › Los Angeles
Los Angeles, CA 的 多發性骨髓瘤 臨床試驗
17 項針對 多發性骨髓瘤 的研究正在 Los Angeles（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
招募中3 期
- USC Norris Comprehensive Cancer Center, Los Angeles
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
招募中3 期
- Valkyrie Clinical Trials, Los Angeles
Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
招募中4 期
- Berenson Cancer Center, Los Angeles
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
招募中3 期
- Valkyrie Clinical Trials, Los Angeles
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
招募中2 期
- The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
招募中2/3 期
- Cedars-Sinai Medical Center /ID# 278238, Los Angeles
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
招募中3 期
- UCLA Hematology/Oncology - Santa Monica, Los Angeles
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
招募中2 期
- UCLA Hematology/Oncology - Westwood (Building 200 Suite 214), Los Angeles
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
招募中1/2 期
- University of Southern California /ID# 272414, Los Angeles
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
招募中3 期
- Clinical Research Advisors (Korea Town Satellite Location), Los Angeles
- Clinical Research Advisors (West Hollywood Satellite Location), Los Angeles
- Valkyrie Clinical Trials, Los Angeles
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
招募中1/2 期
- GSK Investigational Site, Los Angeles
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
招募中1/2 期
- Research Site, Los Angeles
Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
招募中1 期
- Cedars-Sinai Medical Center, Los Angeles
Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma
招募中
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
- Cedars Sinai Medical Center, Los Angeles
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
招募中3 期
- UCLA Medical Center, Los Angeles
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
招募中1/2 期
- University of California Los Angeles (UCLA), Los Angeles
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
招募中1/2 期
- Valkyrie Clinical Trials, Los Angeles
其他城市的 多發性骨髓瘤 試驗
- New York City, NY60 項研究
- Boston, MA42 項研究
- Atlanta, GA42 項研究
- Houston, TX38 項研究
- Durham, NC37 項研究
- Nashville, TN32 項研究
- Denver, CO27 項研究
- St. Louis, MO24 項研究
- Rochester, MN24 項研究
- Columbus, OH24 項研究
- Baldwin Park, CA23 項研究
- Edison, NJ22 項研究
Los Angeles 的其他研究
- 非小細胞肺癌87 項研究
- 癌症（所有類型）74 項研究
- 乳癌73 項研究
- 前列腺癌61 項研究
- 大腸直腸癌59 項研究
- 轉移性癌症57 項研究
- 卵巢癌50 項研究
- 肺癌45 項研究
- 頭頸部鱗狀細胞癌42 項研究
- 胰臟癌35 項研究
- 子宮內膜癌34 項研究
- 黑色素瘤34 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。